U.S. Markets closed

Blog Coverage Stemline Announces Completion of Enrollment for the Stage 3 SL-401 Pivotal Trial

Upcoming AWS Coverage on Jazz Pharmaceuticals Post-Earnings Results

LONDON, UK / ACCESSWIRE / March 24, 2017 / Active Wall St. blog coverage looks at the headline from Stemline Therapeutics, Inc. (NASDAQ: STML) as the Company announced on March 23, 2017, that enrolment of Stage 3 in the SL-401 pivotal trial in blastic plasmacytoid dendritic cell neoplasm (BPDCN) has been completed. The Company also reviewed key milestones for the SL-401 program over the coming year. Stemline is a clinical stage biopharmaceutical Company developing novel therapeutics for oncology indications of unmet medical need. Register with us now for your free membership and blog access at:


One of Stemline Therapeutics' competitors within the Biotechnology space, Jazz Pharmaceuticals PLC (NYSE: JAZZ), reported on February 28, 2017, its financial results for the full year and the fourth quarter of 2016 and provided financial guidance for 2017. AWS will be initiating a research report on Jazz Pharma in the coming days.

Today, AWS is promoting its blog coverage on STML; touching on JAZZ. Get all of our free blog coverage and more by clicking on the link below:


Stage 3 Enrollment

Stemline has completed enrolment of the Stage 3 cohort of the SL-401 pivotal trial in BPDCN. The Company has enrolled 13 first-line BPDCN patients for the Stage III trials. The Company stated that the statistical analysis will be based on evaluable first-line patients. The registration pathway was as per its agreement with the U.S. Food and Drug Administration (FDA). Based on the data outcome of the trial, Stemline plans to use the results generated to support the potential filing of a Biologics License Application (BLA) for full approval in first-line BPDCN, and is targeting possible BLA filing in H2 2017.

For the Stage III multicenter, pivotal trial Stemline has enrolled 47 BPDCN patients at seven centers in the US. The 47 BPDCN patients were comprised of 32 first-line patients and 15 relapsed/refractory patients dosed at 12 ug/kg/day. Stemline plans to provide a clinical update on patients enrolled in Stages 1 and 2 at a medical conference around mid-year, with top-line data from Stage 3 expected in H2 2017. Stemline plans to continue to enroll both first-line and relapsed/refractory BPDCN patients under the current protocol. SL-401 received Breakthrough Therapy Designation (BTD) by the FDA in August 2016.

BLA Preparation and Pre-Commercial Activities

Stemline announced that its clinical, preclinical, manufacturing, and regulatory teams are working toward a timely and comprehensive potential BLA filing. Ongoing efforts include compiling the necessary supportive data and assembling the BLA modules, including clinical, clinical pharmacology, non-clinical, and CMC (chemistry, manufacturing, and controls). In parallel, the Company's commercial team is working to define the BPDCN market landscape, including factors related to patient flow, market access and pricing considerations, all with an eye toward setting the stage for a successful launch of SL-401, if approved.

Other Trial Updates

Stemline is performing additional Phase 2 trials with SL-401 and is enrolling patients with other malignancies including high-risk myeloproliferative neoplasms (MPN) and acute myeloid leukemia (AML) in remission with minimal residual disease (MRD). A Phase 1/2 trial of SL-401 in combination with pomalidomide is enrolling patients with relapsed/refractory multiple myeloma. The Company also has a Phase 1 dose escalation trial and is enrolling patients with advanced tumors with SL-801, a novel oral small molecule reversible inhibitor of XPO1. A Phase 2 trial with SL-701, an immunotherapy designed to activate the immune system to attack tumors has completed dosing and patients with second-line glioblastoma are being followed for survival.

Financial Results

On March 16, 2017, Stemline announced that for Q4 FY16 it had a net loss of $10.0 million, or $0.56 per share, compared with a net loss of $10.2 million, or $0.58 per share, for Q4 FY15. The Company's Research and development expenses were $7.3 million for Q4 FY16, which reflects a drop of 8%, compared with $7.9 million for Q4 FY15.

Stemline ended Q4 FY16 with $67.6 million in cash, cash equivalents, and investments compared to $74.3 million as of September 30, 2016, which reflects a cash burn of $6.7 million for the reported quarter. Subsequent to year end 2016, Stemline completed a follow-on public offering during January 2017 raising $48.2 million in net cash proceeds bringing total cash, cash equivalents, and investments to approximately $110.0 million as of March 16, 2017.

Stock Performance

At the closing bell, on Thursday, March 23, 2017, Stemline Therapeutics' stock dropped 5.03%, ending the trading session at $8.50. A total volume of 365.52 thousand shares were traded at the end of the day. In the last month and previous twelve months, shares of the Company have surged 27.82% and 83.98%, respectively. At Thursday's closing price, the stock's net capitalization stands at $212.93 million.

Active Wall Street:

Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

AWS has not been compensated; directly or indirectly; for producing or publishing this document.


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst, for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.


AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/.


For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@activewallst.com

Phone number: 1-858-257-3144

Office Address: 3rd floor, 207 Regent Street, London, W1B 3HH, United Kingdom

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active Wall Street